ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #141301

Jahr Robert Charles bought OTLK

July 1, 2025 · Form 4 insider transaction

Jahr Robert Charles bought 800,000 shares of Outlook Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 8 days after the transaction.

Direction
Acquired (buy-side)
Shares
800,000
Price
$0.00
Total value
N/A
InsiderJahr Robert Charles
RoleOfficer
CompanyOutlook Therapeutics, Inc. (OTLK)
SecurityStock Option (Right to Buy)
Transaction codeA — Grant or award
Transaction dateJuly 1, 2025
Filing dateJuly 9, 2025
Shares owned after800,000
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

25% of the shares subject to the option will vest on July 1, 2026, with the remaining shares vesting in 36 equal monthly installments over the following three (3) years, subject to the Reporting Person's Continuous Service to the Issuer through each such vesting date.

View the original Form 4 on SEC EDGAR